ArticleMicrobial cell factories2026
Functional characterization of steroid hydroxylation by cytochrome P450 enzymes from Rhodococcus erythropolis KB1.
Article in Microbial cell factories, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Cytochrome P450 monooxygenases (CYPs) constitute a versatile family of biocatalysts capable of regio- and stereoselective hydroxylation, offering significant potential for pharmaceutical synthesis and the environmental remediation of endocrine-disrupting steroids. Although their synthetic utility is widely recognized, the mechanistic basis of their activity, particularly in bacteria, remains insufficiently explored. Building on prior discovery of steroid-degrading activity in Rhodococcus erythropolis KB1, in this study, we functionally characterized three putative P450 enzymes (CYP125ARh1, CYP125ARh2, and CYP153ARh3) identified from its genome. Substrate-binding assays demonstrated strong affinity toward progesterone and testosterone, but negligible affinity for 11β-hydroxysteroids, including cortisol and corticosterone. In vitro conversion assays revealed that all three enzymes specifically catalyze 16α-hydroxylation of progesterone and testosterone, although with varying catalytic efficiencies. Among them, CYP125ARh2 was identified as the most efficient enzyme, achieving near-quantitative conversion of progesterone (88%) and testosterone (62%). Kinetic analysis further underscored the superior catalytic properties of CYP125ARh2, which displayed lower Michaelis constants (Km = 16.41 ± 1.97 µM for progesterone and 24.50 ± 2.60 µM for testosterone) and higher turnover rates (Vmax = 6.05 ± 0.16 µM/min and 5.09 ± 0.13 µM/min, respectively). The superior catalytic efficiency of CYP125ARh2 originates from its unique active site architecture, which integrates a pre‑organized, synergistic residue network with pronounced induced‑fit plasticity. This structural synergy enables precise substrate positioning and optimal reaction geometry, thereby rationalizing its high 16α‑hydroxylation activity toward both progesterone and testosterone. These findings highlight CYP125ARh2 as a promising template for engineering high-performance biocatalysts. Overall, this work provides foundational insights into the role of the P450 enzymes in steroid chemistry and the biodegradation of steroidal pollutants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.